Sentences with phrase «many small biotech»

Having those multiple partners is key, because one of the big risks any small biotech faces is that the partner decides to walk away from its development program — not surprising, since most drug development programs fail.

The lines between Big Pharma and small biotech are eroding.

The «microbiome,» or the collection of organisms that reside within the human body (especially the gut), has become a big new interest area for a number of major pharma companies like Merck and smaller biotechs alike.

There's also significant investment supporting small biotech companies and Linear has invested substantially in attracting both the American and Chinese markets including engaging Mandarin speaking staff, translating materials and running meetings in Mandarin.

The head of Riot Blockchain, a small biotech company - turned - crypto, has made hundreds of thousands of dollars in stock sales already.

The approach comes at a time of renewed interest by large drugmakers in smaller biotech firms, with U.S. - based Celgene clinching a deal to buy Impact Biomedicines for up to $ 7 billion on Sunday and Japan's Takeda Pharmaceutical agreeing last week to buy another Belgian biotech group TiGenix for $ 630 million.

Many pharmaceutical companies continue to work on treatments for neurological diseases, as do many smaller biotech firms and academic medical research centers, and funding sources for these pursuits include private foundations as well as governments.

H.I.G.'s seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer.

On November 21st, a relatively small biotech company named Gilead Sciences (GILD) made headline news in the pharmaceutical investment community when it acquired a little - known hepatitis C drug developer named Pharmasset Inc. (VRUS), for $ 10.8 billion, in an all - cash deal.

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease Source: Streetwise Reports (5/2/18) In the second of a two - part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small - cap companies targeting big - ticket indications and their potential to drive blockbuster value for both patients and investors.

With smaller biotechs having seen some incredible performance over the past year, it's not surprising to see the SPDR outperforming its iShares counterpart.

Julian was also CEO of a small biotech company.

She participated in collaborations with small biotech companies and big pharma.

These include the BioRegio initiative, aimed at establishing a «competence network» in biotech, the BioFuture competition for young scientists, and BioChance for small biotech start - ups.

In a small biotech firm, by contrast, «you are part of the whole picture and you're more involved in what goes on in the entire company.»

In 2006, Merck also bought two small biotech firms with which it had been partnering, GlycoFi of Lebanon, New Hampshire, and Abmaxis of Santa Clara, California.

The move followed the company's acquisition of another biotech, KuDOS Pharmacetuicals, in 2005 and several agreements with small biotechs to co-develop drugs.

But the aspect of the work I enjoy most, and one that I think differentiates research in a small biotech company from research in larger institutions and a great many university departments, is that competition is replaced by cooperation.

«In terms of learning potential, I thought that there would be more to learn in a small biotech company than in big pharma,» he explains.

«In some respects, working in a small biotech is like climbing a steep ladder.

San Francisco - based Genentech, for example, started out as a small biotech in 1976.

Seven years ago, when I completed my Ph.D. and joined a small biotech company, my assigned title was Scientist.

Smaller biotech company GeneMedix has a plant in Ireland.

It's not big pharmaceutical companies driving the demand there, he says, but small biotech companies who've realized they can capitalize on the enormous amount of publicly available health and genomics data.

Giant pharmaceutical and smaller biotech firms are searching for epigenetic compounds to boost learning and memory.

«A lot of small biotech companies have been affected by the economic situation.

«I think it may be up to smaller biotech companies and academia to come up with new drugs,» Littman says.

Most small biotechs have to publicize every step of their early research in a scramble to raise money, Moore notes.

You need that kind of communication just to get anything done in a small biotech company, says Douglas Gjerde, CEO of San Jose, California - based PhyNexus.

University and government departments, and small biotech companies, employ me to advise them on bioinformatics and structural biology research.

And animal advocates who want to influence business could consider investing in the small biotechs and large pharmaceutical companies that are working to develop alternatives to animals in research.

The reason some hiring managers are more critical of industry postdocs is that a number of smaller biotech companies consider positions at the postdoc level to be «cheap pairs of hands» jobs and not independent research positions.

Jane works at BioPharmGene, a small biotech company.

So, when I go to visit a small biotech company in California that is very casual, it makes sense to be in the same kind of attire.

So I looked for postdoctoral positions as well as for positions in smaller biotech companies.

Susan Schade, a UAB alumna who now does research for a small biotech company in Birmingham, says that the IR helped her in its «exposure to different career paths and networking» and allowed her «to make contact with all kinds of people not at UAB.»

Now Poirier is collaborating with large pharmaceutical companies and small biotech firms that are developing and manufacturing memory - enhancing drugs.

Researchers at Protein Sciences Corporation, a small biotech in Meriden, Connecticut, genetically modified a virus that infects caterpillar cells to produces hemagglutinin, a coat protein of the influenza virus that triggers antibodies.

Researchers in government and small biotech firms are trying to pick up some of the slack and are searching for agents that work in new ways.

«I think there is more open opportunity in small biotech for people with an academic background,» he says.

Blackwell has started a small biotech company in Madison with that as her goal — plotting a future jump in scale from plants to people.

At the small biotech startup where she worked when her son was born, her bosses began to resent her need for pumping breaks, even though she continued to work on the phone or over email while pumping in her office, she says.

Braithwaite adds, «small biotech is really fueled by innovation,... so it's very important to be getting experience in techniques that are really the cutting edge of science and not just the old standard techniques.»

Sure, the smaller biotech companies can be squirrelly at times, but nothing beats the odd behavior of some Fortune 100 companies.

Additionally, he suggests working at a small biotech or pharmaceutical company.

But because they're a small biotech company, with high risk of default (i.e., a high risk of not paying off their debts), they would have to pay a very high interest rate in order to make the bond attractive enough for investors to purchase it.

Now, a small biotech start - up is providing an alternative for those critics who want to mine Iceland's genetic riches but do not want to cooperate with the company that has exclusive rights to the database.

These include government or private nonprofit funders of basic research, such as the National Institutes of Health in the United States or the Wellcome Trust in the United Kingdom; academic scientists; multinational pharmaceutical firms and smaller biotech companies; and, at the end of the line, government regulatory agencies responsible for drug approval.

With more than 1,200 international actors from 35 + countries, such as big pharma, emerging and small biotech, diagnostics companies, pre-seed / seed / Series A investors, as well as professionals from tech transfer, academia and research institutions, BioFIT is the leading partnering event in Europe for technology transfer, academia - industry collaborations and early - stage innovations in the field of Life Sciences.

I'm looking forward to being a part of this Philadelphia research hub and connecting with researchers and small biotechs in the region and beyond.»